Background: Case series suggest a possible association between bariatric surgery
| INTRODUCTION
The incidence of IBD is rising worldwide. 1 Although genetics and an aberrant immune response are central in IBD pathogenesis, environmental factors also play a key role. Prior research has highlighted the importance of risk factors such as smoking, medication exposures, diet and vitamin D. [2] [3] [4] [5] [6] [7] One environmental factor that can affect the likelihood of developing IBD is surgery. Appendectomy may increase the risk of CD and appears to have a protective effect against the development of ulcerative colitis (UC) although this effect in UC has been questioned. 8, 9 Recently, there have been case reports of patients developing CD following bariatric surgery. [10] [11] [12] [13] [14] Interestingly, there have also been reports of immune-mediated diseases occurring after weight loss surgery. 15 In order to explore the possible relationship between bariatric surgery and IBD, we first compiled a multicentre descriptive case series. We subsequently examined the association between prior bariatric surgery and risk of new-onset IBD in a large health claims database.
2 | ME TH ODS pharmacies, 1500 hospitals, 800 outpatient facilities and 80 000 physician practices. This resource was previously used for IBDrelated research. 7, 16 Inc, Cary, NC, USA). P values less than 0.05 were considered statistically significant.
| Case series

| RESULTS
| Case series
We identified 15 patients with IBD with a prior history of bariatric surgery (Table 1) . A summary of the clinical characteristics of these cases are presented in Table 2 . 
| Case-control study
After applying all inclusion and exclusion criteria, we identified 8980 IBD cases and 43 059 controls ( Figure 1 ). There were 253 patients with a bariatric code (surgery or past history) ( Table 3 ). After adjusting for age, obesity and medication exposures, we found that any prior bariatric surgery was associated with an increased odds of new-onset IBD (aOR 1.45, 95% CI 1.08-1.94) ( Table 4 A past history of bariatric surgery, but not recent surgery, was associated with both new-onset CD and UC (Table 5 ). Analyses further classifying recent bariatric surgery as preserved or altered intestinal anatomy showed no significant difference in risk (data not shown) when compared to patients without a history of bariatric surgery. However, the number of IBD patients with sufficient data for this subgroup analysis was small (n = 19). Since many bariatric patients have a cholecystectomy at the time of bariatric procedure or at a later date, we conducted an additional analysis controlling for cholecystectomy and found that the association between new-onset IBD and past history of bariatric surgery was similar (aOR 1.79, 95% CI 1.24-2.60).
| DISCUSSION
We report one of the largest case series of IBD following bariatric surgery, including some of the first reported cases of UC. We also conducted the first large database study examining the association between prior bariatric surgery and IBD and found that patients with new-onset IBD were significantly more likely to have a past history of bariatric surgery than matched controls.
Previously, 9 cases of IBD following bariatric surgery were reported in the literature. [10] [11] [12] [13] [14] All of these prior reports were of patients developing CD. Similar to the findings of our case series, the majority of reported cases were women, tended to be middle aged and were mostly diagnosed years after the bariatric procedure, and the majority had Roux-en-Y gastric bypass. The increased proportion of women is likely because more bariatric surgeries are done in women than men. 23 In this case series, we also report patients who developed UC after bariatric surgery as well as a minority of cases of IBD following bariatric procedures other than Roux-en-Y, specifically gastric band and sleeve gastrectomy.
Given the limited level of evidence provided by case reports and the inability to state if these individual post-bariatric cases are expected based on IBD incidence rates, we next performed an analysis using a large, national database. Both CD and UC patients had higher odds of having a history of bariatric surgery in the database. However, the association was only statistically significant in UC with a strong trend in CD.
Although the database is unable to provide the same level of detail as the case reports, the finding that the significant association which was driven by a past history of bariatric surgery (four or more years) is consistent with the pattern seen in case series. Interestingly, recent research suggests a long preclinical phase in IBD in which immunologic changes may gradually develop years prior to diagnosis. 24 The mechanism by which bariatric surgery may increase the risk of IBD is not entirely clear. Alterations in the microbiome following bariatric surgery may be a plausible explanation. Many studies have
T A B L E 1 Case series vignettes
Case descriptions 1. Man who underwent Roux-en-Y gastric bypass at age 26, subsequently diagnosed with Crohn's disease, involving jejunum, ileum and colon, at age 42 when he presented with large volume diarrhoea and rectal bleeding. He has mild but chronically active disease. Of note, he underwent renal transplant 5 mo prior to diagnosis and has remained on azathioprine, tacrolimus and prednisone for this purpose. Last colonoscopy with mild-moderate persistent ileitis 2. Woman who underwent Roux-en-Y gastric bypass at age 38 and was subsequently diagnosed with ulcerative proctosigmoiditis at age 44. She has mild but chronically active disease on oral and rectal 5-ASA 3. Woman with IBD-U (pancolitis), who underwent Roux-en-Y gastric bypass at age 53 and was subsequently diagnosed with IBD at age 55. Three years after gastric bypass surgery, she developed SMA thrombosis and mesenteric ischaemia, requiring extensive small bowel and partial colonic resection. Because of this, she has short bowel syndrome and requires TPN. Her colitis remains quiescent on 5-ASA 4. Woman who underwent Roux-en-Y gastric bypass at age 40, although was subsequently reversed 1 year later. She was diagnosed with ileocolonic Crohn's disease at age 43. She has had moderate to severe exacerbations with intervening remission. Her disease course was complicated by an intra-abdominal abscess, terminal ileal stricture with obstruction and internal penetrating disease over the 5 y after diagnosis. She is now doing well on infliximab 5. Woman who underwent laparoscopic placement of adjustable gastric band at age 42 and was subsequently diagnosed with ileocolonic Crohn's disease at age 46. Her disease has been mild, and she has been maintained on 5-aminosalicylates, with two short courses of budesonide for flares 6. Woman who underwent Roux-en-Y gastric bypass at age 42 and was subsequently diagnosed with Crohn's colitis at age 43. She presented with large volume diarrhoea and rectal bleeding. Also with hypoalbuminaemia and erythema nodosum. She has chronically active moderate to severe disease and has had partial response to steroids, three anti-TNF agents and methotrexate. Currently maintained on anti-TNF 7. Woman who underwent Roux-en-Y gastric bypass at age 36 and was diagnosed with ileocolonic Crohn's disease at age 46. She developed a free perforation soon after diagnosis and underwent colectomy with ileostomy. She is now in remission on thiopurine alone 8. Woman who underwent Roux-en-Y gastric bypass at age 46 and subsequently developed ileocolonic Crohn's disease at age 48. She presented with diarrhoea and anaemia, requiring hospitalisation at the time of initial diagnosis. She has been in remission on thiopurine 9. Woman who underwent biliopancreatic diversion with duodenal switch at age 41, and subsequently diagnosed with ileal Crohn's disease at age 46. She presented with diarrhoea and improved with a short course of prednisone. She now has mildly active disease on 5-aminosalicylates 10. Woman who underwent Roux-en-Y gastric bypass at age 26 (complicated by post-operative abdominal infection) and developed ulcerative colitis at age 28. Presented with diarrhoea, rectal bleeding and anaemia. Required hospitalisation at diagnosis and successfully treated with IV steroids. Now with clinical remission maintained on combination therapy with anti-TNF and thiopurine 11. Woman who underwent Roux-en-Y gastric bypass surgery at age 52 and subsequently developed ulcerative proctitis at age 58. A late complication of her bariatric surgery was anastomotic stenosis. Her ulcerative proctitis has been well controlled on mesalazine suppositories alone 12. Woman who underwent laparoscopic placement of adjustable gastric band at age 30. She was then diagnosed with ulcerative colitis at age 38.
She presented with rectal bleeding with mild inflammation. Previously used oral and rectal mesalazine therapy. Not currently on any medications 13. Woman who underwent laparoscopic placement of adjustable gastric band at age 31 and subsequently developed Crohn's disease at age 34.
Treated with 5-ASA alone 14. Woman who underwent Roux-en-Y gastric bypass at age 40. Diagnosed with ileal Crohn's disease at age 47. Presented with diarrhoea. Also with small joint arthritis unrelated to disease activity. On 5-ASA therapy alone 15. Man who underwent laparoscopic placement of adjustable gastric band at age 40 and then sleeve gastrectomy at age 49. Five months after his sleeve gastrectomy, he developed Crohn's colitis. He presented with abdominal pain. His disease was moderately active at diagnosis and has been chronically active since that time. He is currently on anti-TNF therapy 5-ASA, 5-aminosalicylates; SMA, superior mesenteric artery; TNF, tumour necrosis factor; TPN, total parental nutrition.
UNGARO ET AL. There are also various hormonal changes that occur following bariatric surgery including increases in adiponectin and glucagon-like peptide (GLP-1) and decreases in leptin. 35 Adiponectin may play both anti-and pro-inflammatory roles and is increased in the mesenteric adipose tissue of CD patients. 36, 37 In contrast, leptin antagonists are being studied as possible therapeutics in IBD. 38 Last, animal studies have suggested that bariatric surgery may lead to changes in intestinal epithelium including alterations in cell proliferation, changes in villous and crypt height and increased permeability. | 1131 who lose weight through diet and exercise. 41 These findings suggest a differing impact of bariatric surgery in preclinical vs established IBD.
There are several strengths and limitations to this study.
Strengths include the large sample size and utilisation of a nationally representative database. In addition, to decrease the chance of misclassification, controls had no IBD-related prescriptions and no conditions associated with risk of IBD. Limitations include utilisation of retrospective data and since the database included de-identified health claims data, the inability to directly validate cases and to determine whether those designated as new onset were definitively incident cases. Similarly, we are unable to verify bariatric surgery and obesity codes which may lead to misclassification bias. However, the criteria used to define cases were selective, similar to prior published studies, and applying them narrowed the cohort from over one million patients down to around 9000 patients. 17, 18 This is likely a conservative number of new IBD cases. There are over 60 000 new cases of IBD estimated to occur each year in the United
States. 42 The cohort utilised for this analysis was derived from a database with 220 million patients (compared with 310 million people in the United States). The primary analysis included 1 year of data in which new diagnoses of IBD were considered (2012). On the basis of prior incidence estimates, the expected incidence rate within the study cohort would be 42 580 new cases per year. As 8980 new IBD cases were identified based on the inclusion criteria, this is likely to be an underestimate of the true incidence rate within the database. The database did not include reliable information on other potential confounders including smoking, diet, early life exposures or family history. Last, since patients with the past history of bariatric surgery were exposed prior to database entry, there is the possibility of confounding by indication, most notably obesity. We controlled for obesity although this may not completely remove this possibility.
Some prior research has suggested that obesity may increase the risk of developing IBD, but this is inconsistent across studies. 41 Of note, a recently published case series of IBD following bariatric surgery had similar findings to our study. 43 control findings, the average age of onset was middle-age (40s-50s), the majority of patients were female, and the time between surgery and IBD diagnosis was typically years. Using a registry of bariatric patients at Mayo Clinic, the authors found a higher than expected standardised incidence ratio for IBD following bariatric surgery.
In summary, we report one of the largest case series to date of patients with de novo IBD following bariatric surgery and found that the past history of bariatric surgery was significantly associated with new-onset IBD in a health claims database. The overall positive impact of bariatric surgery on obesity, including improvement in comorbid conditions and decreased mortality, certainly outweighs the possible increased risk of IBD but could offer potential new insights into contributors to disease pathogenesis. 44 The potential association between prior bariatric surgery and new IBD highlights the need to perform a thorough work up and have a broad differential diagnosis in post-bariatric surgery patients with new gastrointestinal symptoms.
However, given the nature of administrative database studies, we cannot draw causative conclusions and further prospective studies are needed to confirm this association and delineate if certain types of bariatric surgeries have differential effects on risk of IBD.
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